Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Editas Medicine, Inc. EDIT

Set alert

Price alert · EDIT

All alert types
2.57 USD -0.10 -3.75%

At close · Nov 2

2.59 +0.02 +0.67%

After hours · Nov 2, 4:13 PM ET

Bid
2.56 × 2
Ask
2.57 × 25
2.55 Day range 2.78
1.66 52-week range 3.94
YTD
+25.37%
1 year
-16.56%
Open
2.71
Prev close
2.67
Mkt cap
394.70M
Vol
1.24M
Avg vol
2.69M
EPS
-0.68
P/E
0.00
Div yield
0.00%
More statistics
Low
2.55
High
2.78
Forward P/E
-0.53
Beta
2.01
Short ratio
6.70
Inst. own
70.94%
Dividend
0.00
Ex-div date
50-d avg
2.60
200-d avg
4.55
1y target
3.67

3M chart

Chart tools
Interval
1m5m15m30m

Signals (19)
NameDateAgo
SMA: BearishNov 2, 20269 hours ago
SMA: BearishOct 30, 20263 days ago
SMA: BullishOct 28, 20265 days ago
SMA: BullishOct 28, 20265 days ago
MACD: Buy SignalOct 27, 20266 days ago
MACD: Sell SignalOct 14, 20262 weeks ago
SMA: BearishOct 12, 20263 weeks ago
SMA: BearishOct 12, 20263 weeks ago
SMA: BullishOct 9, 20263 weeks ago
SMA: BullishOct 8, 20263 weeks ago
MACD: Buy SignalOct 5, 20264 weeks ago
SMA: BearishSep 23, 20261 month ago
SMA: BullishSep 22, 20261 month ago
SMA: BearishSep 9, 20261 month ago
SMA: BearishSep 9, 20261 month ago
MACD: Sell SignalSep 8, 20261 month ago
SMA: BearishAug 12, 20262 months ago
SMA: BullishAug 11, 20262 months ago
MACD: Buy SignalAug 6, 20262 months ago

Discussion (212)

Sign in to join the discussion

ZirK EDIT 1 year ago #1

Bagholder for very long time

Xsman EDIT 2 years ago #2

8.31 first target

Jitin Goyal EDIT 3 years ago #5

Rumours circulating that Editas has received an offer to be acquired at a valuation of $1.5 bn

Jitin Goyal EDIT 3 years ago #6

This stock will be trading at $17-20 in a couple of weeks.

Jitin Goyal EDIT 3 years ago #7

Massively undervalued stock. Average analyst price target is $16, highest is $30. Crazy that it’s trading at such low levels right now.

Jitin Goyal EDIT 3 years ago #8

Stifel analyst Dae Gon Ha upgraded Editas Medicine (NASDAQ: EDIT) from Hold to Buy with a price target of $17.00 (from $9.00).

The analyst comments "We are upgrading EDIT shares to Buy and increasing TP to $17 (vs. $9 previously). We think EDIT-301's (sickle cell disease [SCD]) progress has received minimal credit from investors. But with YE23 goal to dose n=20, in addition to important regulatory insights expected from exa-cel (CRSP, covered by Stifel colleague Ben Burnett), we think EDIT-301 deserves a fresh look. Within, we discuss the disconnect between EDIT and CRSP valuations - at comparable time points in development, EDIT-301's clinical profile thus far (vs. exa-cel), our optimism - both clinically and regulatory - in EDIT-301's strategy (i.e., HBG1/2 promoter region), market receptivity - and TAM - for follow-on gene editing like EDIT-301, and potential upside from the IP dispute.